亚硝酸钠与异槲皮素联合治疗对CKD患者内皮功能障碍的随机2期试验
这项随机双盲安慰剂对照2期预试验纳入70例非透析CKD患者,比较亚硝酸钠(40 mg每日两次)联合异槲皮素(225 mg每日一次)12周与安慰剂对内皮功能的影响。结果显示血流介导的血管舒张净变化为0.8%(95%CI -0.9至2.5),内皮功能、炎症、氧化应激生物标志物及安全性指标均无显著组间差异。
要点
- 联合治疗未显著改善CKD患者血流介导的血管舒张。
- 内皮功能、炎症和氧化应激生物标志物无显著组间差异。
- 治疗未增加不良事件,安全性良好。
核心结论
- 亚硝酸钠联合异槲皮素未显著改善CKD患者血流介导的血管舒张或其他内皮功能生物标志物,但未增加不良事件。
研究设计与样本
- 随机双盲安慰剂对照2期预试验,纳入70例非透析CKD患者,35例接受亚硝酸钠(40 mg每日两次)联合异槲皮素(225 mg每日一次)12周,35例接受安慰剂,采用意向性分析。
主要发现
- 12周时治疗组血流介导的血管舒张增加1.1%(95%CI -0.1至2.3),安慰剂组增加0.3%(95%CI -0.9至1.5),净变化0.8%(95%CI -0.9至2.5)。
- 内皮功能障碍生物标志物(血管黏附分子-1、细胞间黏附分子-1、E-选择素、vWf、内皮抑素、不对称二甲基精氨酸)变化组间无显著差异。
- 炎症生物标志物(TNF-α、IL-6、C反应蛋白、IL-1受体拮抗剂、单核细胞趋化蛋白-1)和氧化应激标志物(氧化LDL、硝基酪氨酸)变化组间无显著差异。
- eGFR、尿白蛋白-肌酐比值、高铁血红蛋白及不良事件变化组间无显著差异。
临床怎么用
- 该联合方案未显示改善CKD患者内皮功能的获益,不推荐用于此目的。
局限性
- 为2期预试验,样本量较小(70例),可能不足以检测微小差异。
- 干预时间为12周,长期效应未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Endothelial dysfunction is common among patients with CKD. We tested the efficacy and safety of combination treatment with sodium nitrite and isoquercetin on biomarkers of endothelial dysfunction in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This randomized, double-blind, placebo-controlled phase 2 pilot trial enrolled 70 patients with predialysis CKD. Thirty-five were randomly assigned to combination treatment with sodium nitrite (40 mg twice daily) and isoquercetin (225 mg once daily) for 12 weeks, and 35 were randomly assigned to placebo. The primary outcome was mean change in flow-mediated vasodilation over the 12-week intervention. Secondary and safety outcomes included biomarkers of endothelial dysfunction, inflammation, and oxidative stress as well as kidney function, methemoglobin, and adverse events. Intention-to-treat analysis was conducted. RESULTS: Baseline characteristics, including age, sex, race, cigarette smoking, history of hypertension and diabetes, use of renin-angiotensin system blockers, BP, fasting glucose, lipid profile, kidney function, urine albumin-creatinine ratio, and endothelial biomarkers, were comparable between groups. Over the 12-week intervention, flow-mediated vasodilation increased 1.1% (95% confidence interval, -0.1 to 2.3) in the treatment group and 0.3% (95% confidence interval, -0.9 to 1.5) in the placebo group, and net change was 0.8% (95% confidence interval, -0.9 to 2.5). In addition, changes in biomarkers of endothelial dysfunction (vascular adhesion molecule-1, intercellular adhesion molecule-1, E-selectin, vWf, endostatin, and asymmetric dimethylarginine), inflammation (TNF-α, IL-6, C-reactive protein, IL-1 receptor antagonist, and monocyte chemoattractant protein-1), and oxidative stress (oxidized LDL and nitrotyrosines) were not significantly different between the two groups. Furthermore, changes in eGFR, urine albumin-creatinine ratio, methemoglobin, and adverse events were not significantly different between groups. CONCLUSIONS: This randomized phase 2 pilot trial suggests that combination treatment with sodium nitrite and isoquercetin did not significantly improve flow-mediated vasodilation or other endothelial function biomarkers but also did not increase adverse events compared with placebo among patients with CKD. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Nitrite, Isoquercetin, and Endothelial Dysfunction (NICE), NCT02552888.
引用
- Chen J, Hamm LL, Bundy JD, et al. Combination Treatment with Sodium Nitrite and Isoquercetin on Endothelial Dysfunction among Patients with CKD: A Randomized Phase 2 Pilot Trial. Clin J Am Soc Nephrol. 2020. PMID: 33023894. doi:10.2215/CJN.02020220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。